Advertisement

Topics

Latest "ConSynance Therapeutics, Inc." News Stories

02:45 EST 14th November 2018 | BioPortfolio

Here are the most relevant search results for "ConSynance Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about ConSynance Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ConSynance Therapeutics, Inc. for you to read. Along with our medical data and news we also list ConSynance Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of ConSynance Therapeutics, Inc. Companies for you to search.

Showing "ConSynance Therapeutics" News Articles 1–25 of 7,900+

Tuesday 13th November 2018

Esperion Therapeutics Inc ESPR Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryEsperion Therapeutics Inc Esperion, a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes oncedaily, oral and lowdensity lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated lowdensity lipoprotein cholesterol LDLC. Its lead product candidate, Bempedoic acid is an ATPcitrate lyase inhibitor which is ...


Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2018

Message from the CEO The third quarter was dominated by extensive preparatory work relating to the planned phase III study, called “The Connection Study”. In addition to chosing the CRO (Premier Research) we have strengthed our own organization to be able to handle the large study of more than 2,000 pre-term infants. The preparations are considerable, as this work is characterized by coord...

Ulcers Global Clinical Trials Review, H2, 2018 [Report Updated: 28092018] Prices from USD $2500

Ulcers Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Ulcers Global Clinical Trials Review, H2, 2018" provides an overview of Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The repor...


ConSynance Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryConSynance Therapeutics Inc ConSynance Therapeutics, formerly Concerted Therapeutics Inc is a drug discovery company that concentrates on the development of new therapeutic solutions for unmet medical needs. The company provides pipeline programs such as CSTI100, CSTI200, and CSTI300, among others. It develops pipeline programs for nonalcoholic steatohepatitis and inflammatory bowel disease...

DermTech Passes State of New York Laboratory Inspection with Zero Deficiencies

DermTech, Inc., the global leader in non-invasive molecular dermatology, passes State of New York, Department of Public Health inspection with zero deficiencies. “We are proud to be part of the New York CLEP accreditation program and to support New York’s melanoma skin cancer testing needs,” said Darryl Garrison, DermTech’s ...

Expansion Therapeutics Hires Elliot Enrich as CMO

Expansion Therapeutics has hired Elliot Ehrich as its chief medical officer. Ehrich was most recently CMO and executive vice president of research and development at Alkermes (NASDAQ: ALKS). He is also a venture partner at 5am Ventures, which incubated Expansion and co-led its $55.3 million Series A financing with Kleiner Perkins, Novartis Venture Fund, and […]

Cipla Acquires Avenue, Primes Play In Pain Amid US Opioid Crisis

Cipla has struck a 'de-risked' deal to acquire the specialty firm Avenue Therapeutics, Inc, for up to $215m as it...   

Propeller Health co-founders share company’s growth and accomplishments

In a phone interview, Propeller Health CEO David Van Sickle and CTO Greg Tracy discussed how their digital therapeutics company has evolved since its founding in 2010.

Agile Therapeutics Inc AGRX Medical Equipment Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryAgile Therapeutics Inc Agile is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol and progestinonly birth control patch. Its pipeline product candidate include AG20015, a onceweekly prescription contraceptive patch designed using ...

Hypopharyngeal Cancer Pipeline Review, H2 2018 [Report Updated: 28092018] Prices from USD $2000

Hypopharyngeal Cancer Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypopharyngeal Cancer Pipeline Review, H2 2018, provides an overview of the Hypopharyngeal Cancer Oncology pipeline landscape.Hypopharyngeal cancer is a term used for tumors of a subsite of the upper aerodigestive tract, and like most other subsite designations...

Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP

Nightstar Therapeutics (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, provided an update on recent achievements and upcoming clinical milestones and reported financial results for the quarter ended September 30, 2018. As quoted in the press release: “We are pleased with the upcoming initiation of the Phase 2/3 expansion study ̷...

Harpoon Therapeutics raises $70M Series C for T-cell engager therapies

The company is currently running a Phase I study in prostate cancer a

Small-Cap Snapshot: Unum Therapeutics shares rise on news of upcoming investor presentation

Small cap names on the move today are: Unum Therapeutics (NASDAQ:UMRX), Beazer Homes (NYSE:BZH), CymaBay Therapeutics Inc (NASDAQ:CBAY), Madrigal Pharmaceuticals (NASDAQ:MDGL). 

Kalytera Announces Next Share Issuance for Services under Payments Agreement with Salzman Group

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 3,963,988 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement announced on June 15, 2018 (the “June 2018 Agreement”).  The post Kalytera Announces Next Share Issuance for Services...

Chinese Distributor/Manufacturer Completes $1 Million Payment to Guided Therapeutics and Orders Parts in Anticipation of Launch Next Year

Guided Therapeutics, Inc. (OTC Pink: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, provided an update of the progress made working together with its Chinese co-manufacturing partner and commercial sales distributor for China, Shandong Yaohuo Medical Device Technology Company, Ltd. Shandong completed...

FDA Grants DeNovo Clearance to Atlantic Therapeutics for INNOVO® Therapy Device to Treat Stress Urinary Incontinence

INNOVO® is the first ever transcutaneous electrical stimulator cleared by the FDA, offering US women a safe, clinically effective and non-invasive choice to treat stress urinary incontinence In its pivotal multi-centre randomized controlled clinical trial, 87.2% of INNOVO® users were dry or mild after a 12-week treatment p...

Expansion Therapeutics Names Elliot Ehrich, MD, Chief Medical Officer

- Former EVP of R&D and Chief Medical Officer at Alkermes joins Expansion to advance portfolio of medicines targeting RNA-mediated diseases - Expansion Therapeutics, Inc., a biotechnology company focused on advancing transformative medicines to patients with RNA-mediated diseases, announced today the appointment of Elliot Ehrich, M.D., as Ch...

Tempest Therapeutics Reports Proof of Mechanism Data for First-in-Class PPAR Alpha Antagonist

--Compelling preclinical data implicate PPAR as a key metabolic checkpoint for tumor growth-- Tempest Therapeutics Inc. presented a poster at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C., describing lead compound TPST-1120’s two-pronged mechanism of directly targeting tumor cells dependent on fatty acid metabolism and dr...

Novus Therapeutics Reports Third Quarter 2018 Financial Results

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended September 30, 2018. “This is an exciting time for the company as we transition into the clinic with a potential first-in...

Sigilon Therapeutics Announces Appointment of Four New Members of Senior Management Team

Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its lead therapeutic candidate into clinical trials. Deya Corzo, M.D., FACMG, joins the company as Chief Med...

Helperby Therapeutics and UCLA to Collaborate on New Fast Track Antibiotic Therapies Aiming to Bring New Sophisticated Combination Therapies to Market in a Much-Reduced Timescale

WHO World Antibiotic Awareness week 2018 [12-18 November] Helperby Therapeutics Ltd (Helperby), a leading biopharmaceutical company wholly focused on developing the next generation of combination antibiotics, has announced a collaboration with Dr. Pamela Yeh and her team at the Department of Ecology and Evolutionary Biology, University of California, L...

AsclepiX Therapeutics Raises $5M in New Funding

Financing will advance clinical development of the Company’s lead product AXT107 AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today announced that it has raised $5 million in Convertible Note funding, led by Barer & Son Capital with additional funds from Raph...

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q3 2018 Results - Earnings Call Transcript

Agilvax Appoints Joseph Patti, Ph.D. as Executive Chairman

Adds significant drug and business development experience to Agilvax as it transitions into a clinical stage company Agilvax, Inc. a biotechnology company developing targeted antibody-based therapeutics for the treatment of various types of cancers announced today that Joseph Patti, Ph.D., will join its Board of Directors as Executive Chairman. ...

Global Crohn's Disease Therapeutics Market Report 2018-2025: Size, Share & Trends ...

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Immune Disorders Drugs Read more...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks